Dr. Nasir Shahab, MD

Dr. Shahab practices at Duly Health and Care Lisle in Lisle, Illinois.

Dr. Shahab's NPI, 1407801061, was assigned on May 23, 2006. Dr. Shahab holds Illinois license 036116892.

Dr. Shahab's primary practice is Duly Health and Care Lisle, at 430 Warrenville Rd., Ste. 110, Lisle, IL 60532. The practice phone is (630) 469-9200.

Dr. Shahab's primary practice is Duly Health and Care Lisle in Lisle, Illinois. Dr. Shahab is also affiliated with Edward Hospital. The medical group on file is DuPage Medical Group. Dmand AI also links Dr. Shahab to 1 more hospital, 1 group practice or clinic and 1 therapy and rehab clinic, each named with a free account. Dr. Shahab's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shahab practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shahab's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shahab is licensed in Illinois.

CMS data shows 106,063 Medicare services from Dr. Shahab across 68 procedure codes in 2024, for 869 Medicare patients. Medicare paid $2,065,861 for them.

CMS counts 869 Medicare patients who saw Dr. Shahab in 2024. The largest group is 65 to 74, with 368 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shahab's median patient age at 73, with 52% women.

In 2024, Dr. Shahab wrote 1,508 Medicare Part D claims for 308 patients. 67% of them were for generic drugs. CMS names the drug for 1,298 of them, across 31 drugs with 11 or more claims each, at $3,759,685 in total drug cost. In 2023, CMS named 791 claims across 23 drugs.

Dr. Shahab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shahab as offering telehealth.

Dmand AI links Dr. Shahab to 3 clinical trials. Conditions studied include Hematologic Neoplasms, Melanoma and Stomach Neoplasms. Exact Sciences Corporation sponsors the most, 3.

CMS Open Payments shows 145 general payments to Dr. Shahab from 32 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Merck Sharp & Dohme Corporation paid the most, $371.